

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

INSIDE INFORMATION PLAN TO REPURCHASE H SHARES OF THE COMPANY

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) as well as the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is of the view that the current trading price of the H shares of the Company (the “**H Shares**”) does not reflect their intrinsic value. Based on the confidence in the Company’s management team, long-term growth potential and financial position, to safeguard the interests of shareholders and enhance investors’ confidence, the Company plans to repurchase a portion of its H Shares in the open market (the “**Repurchase**”). The Board will convene a meeting to consider the resolution in respect of the Repurchase. The Repurchase shall be conditional upon the grant of a special mandate by the shareholders of the Company (the “**Shareholders**”) at the forthcoming general meeting to authorize the Board and any of its authorized persons to deal with all matters in connection with the Repurchase.

Details of the Repurchase Mandate are as follows:

The total amount of H Shares repurchased shall not exceed 10% of the total number of H Shares in issue at the date of passing of such resolution at the general meeting. The repurchase price on any date of the Repurchase shall not be higher by 5% or more than the average closing market price of H Shares for the five preceding trading days on which H Shares were traded on the Stock Exchange. The relevant consideration for the Repurchase will be funded with internal financial resources of the Company. The repurchased H Shares will be subsequently cancelled. The effective term of the Repurchase Mandate will expire on the earlier of (i) the conclusion of the annual general meeting of the Company to be held in respect of the financial year ending 31 December 2024; or (ii) the date on which the Repurchase Mandate given under the special resolution is revoked or varied by a special resolution of the Shareholders in general meeting.

RISK WARNING

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company. Further announcements will be made by the Company as and when appropriate in respect of the Repurchase.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 2 February 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong, Dr. Zou Jianjun and Dr. Wang Gang as executive Directors; Dr. Feng Hui, Mr. Tang Yi and Dr. Li Xin as non-executive Directors; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive Directors.

* *For identification purpose only*